Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 4/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | VEGFA | P15692 | 1/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | FGF1 | P05230 | 1/20 | 0.36 |
| ▸ | FGF2 | P09038 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680059 | 0.94 | LGALS3 (0.49) | LGALS3LGALS4PTPN1MMP9MMP12 | |
| SCHEMBL1775668 | 0.86 | NT5E (0.47) | LGALS3LGALS4PTPN1HPSEVEGFA | |
| SCHEMBL18408882 | 0.85 | HPSE (0.50) | HPSEVEGFAFGF1FGF2 | |
| SCHEMBL7155559 | 0.85 | HPSE (0.50) | HPSEVEGFAFGF1FGF2 | |
| SCHEMBL7155560 | 0.85 | HPSE (0.50) | HPSEVEGFAFGF1FGF2 | |
| SCHEMBL7149766 | 0.84 | HPSE (0.52) | HPSEVEGFAFGF1FGF2 | |
| SCHEMBL7149771 | 0.84 | HPSE (0.52) | HPSEVEGFAFGF1FGF2 | |
| SCHEMBL7150252 | 0.83 | CA1 (0.44) | LGALS3MMP9MMP12CYP3A4CA1 | |
| SCHEMBL1777133 | 0.82 | NT5E (0.43) | LGALS3LGALS4PTPN1HPSEVEGFA | |
| SCHEMBL7154478 | 0.82 | CA1 (0.40) | LGALS3LGALS4CYP3A4LGALS9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511027-B2 | Method of treating hepatitis delta virus infection | GEORGETOWN UNIVERSITY (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1284720-B1 | L-FMAU FOR THE TREATMENT OF HEPATITIS DELTA VIRAL INFECTION | UNIV GEORGETOWN (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1283211-B1 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | UNIV GEORGIA RES FOUND (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6670342-B2 | Administering a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen; 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uridine (L-FMAU) | GEORGETOWN UNIVERSITY | 2003-12-30 | — | — | US | disclosed |
| US-20030158149-A1 | Method of treating hepatitis delta virus infection | CASEY JOHN L (US) | 2003-08-21 | — | — | US | disclosed |
| EP-0748330-B1 | L-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B-VIRUS AND EPSTEIN-BAR VIRUS | UNIV GEORGIA RES FOUND (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1283211-A2 | L-Nucleosides for the treatment of hepatitis B-virus and Epstein-barr virus | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020160980-A1 | Method of treating hepatitis delta virus infection | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC | 2002-10-31 | — | — | US | disclosed |
| US-5808040-A | VIRICIDES | YALE UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5753789-A | Oligonucleotides containing L-nucleosides | YALE UNIVERSITY (US) | 1998-05-19 | — | — | US | disclosed |
| US-5587362-A | VIRICIDES FOR HEPATITIS VIRUS AND EPSTEIN-BAR VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-12-24 | — | — | US | disclosed |
| US-5567688-A | ADMINISTERING SPECIFIED ENANTIOMORPH TO HUMAN INFECTED WITH HEPATITIS B VIRUS | UNIV. OF GA RESEARCH FOUNDATION (US) | 1996-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158149-A1 | Method of treating hepatitis delta virus infection | NSUN3, METTL3, METAP1 | LGALS3 692/4885LGALS4 2141/4885PTPN1 1693/4885 |
| US-20020160980-A1 | Method of treating hepatitis delta virus infection | NSUN3, METTL3, METAP1 | LGALS3 692/4885LGALS4 2141/4885PTPN1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.